Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

Journal of Hepatology

Volumn 68, Issue 5, 2018, Pages 895-903

  Hezode, Christophe ^a   Reau, Nancy ^b   Svarovskaia, Evguenia S ^c   Doehle, Brian P ^c   Shanmugam, Ragavi ^c   Dvory Sobol, Hadas ^c   Hedskog, Charlotte ^c   McNally, John ^c   Osinusi, Anu ^c   Brainard, Diana M ^c   Miller, Michael D ^c   Mo, Hongmei ^c   Roberts, Stuart K ^d   O'Leary, Jacqueline G ^e   Shafran, Stephen D ^f   Zeuzem, Stefan ^g  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c GILEAD SCIENCES   (United States)

^d MONASH UNIVERSITY   (Australia)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

ASTRAL 1; ASTRAL 2; ASTRAL 3; ASTRAL 5; Direct acting antivirals; POLARIS 2; POLARIS 3; Sofosbuvir velpatasvir

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; NS-5 PROTEIN, HEPATITIS C VIRUS; SOFOSBUVIR; VELPATASVIR; VIRAL PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS LOAD; CHRONIC HEPATITIS C; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; GENETIC VARIATION; GENETICS; GENOTYPE; HEPACIVIRUS; HIGH THROUGHPUT SEQUENCING; MULTICENTER STUDY; TREATMENT FAILURE; VIROLOGY;

ANTIVIRAL AGENTS; CARBAMATES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85041605559     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.11.032     Document Type: Article

References (22)

1. Rao, V.B., Johari, N., du Cros, P., Messina, J., Ford, N., Cooke, G.S., Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 15 (2015), 819–824.
2. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 161–176.
3. World Health Organization. Hepatitis C fact sheet, April 2017. http://www.who.int/mediacentre/factsheets/fs164/en/.
4. Liang, T.J., Ghany, M.G., Current and future therapies for hepatitis C virus infection. N Engl J Med 368 (2013), 1907–1917.
5. Smith, D.B., Bukh, J., Kuiken, C., Muerhoff, A.S., Rice, C.M., Stapleton, J.T., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59 (2014), 318–327.
6. Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
7. Kaneko, T., Tanji, Y., Satoh, S., Hijikata, M., Asabe, S., Kimura, K., et al. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun 205 (1994), 320–326.
8. He Y, Staschke KA, Tan SL: HCV NS5A: A Multifunctional Regulator of Cellular Pathways and Virus Replication. In: Tan SL, ed. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK), 2006.
9. Lawitz, E.J., Dvory-Sobol, H., Doehle, B.P., Worth, A.S., McNally, J., Brainard, D.M., et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother 60 (2016), 5368–5378.
10. Feld, J.J., Jacobson, I.M., Hezode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
11. Foster, G.R., Afdhal, N., Roberts, S.K., Brau, N., Gane, E.J., Pianko, S., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
12. Wyles D, Brau, N, Kottilil, S, Daar, E, Workowski, K, Luetkemeyer, A, et al. Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study. In: The International Liver Congress™ EASL - European Association for the Study of the Liver; 2016 13–17 April 2016; Barcelona, Spain; 2016.
13. Jacobson, I.M., Lawitz, E., Gane, E.J., Willems, B.E., Ruane, P.J., Nahass, R.G., et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology, 2017.
14. Zeuzem, S., Mizokami, M., Pianko, S., Mangia, A., Han, K.H., Martin, R., et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J Hepatol 66 (2017), 910–918.
15. I-h, Shih., Vliegen, I., Peng, B., Yang, H., Hebner, C., Paeshuyse, J., et al. Mechanistic characterization of GS-9190 (tegobuvir), a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 55 (2011), 4196–4203.
16. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999), 110–113.
17. Schreiber, J., McNally, J., Chodavarapu, K., Svarovskaia, E., Moreno, C., Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir. Hepatology, 2016.
18. Cheng G, Yu M, Peng B, Lee Y-J, Gong R, Trejo-Martin A, et al. GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage, and a high resistance barrier. Abstr 48th Annual Meeting of the European Association for the Study of the Liver http://wwwnataporg/2013/EASL/EASL_34htm. 2013.
19. Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., Gitlin, N., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
20. Fridell, R.A., Wang, C., Sun, J.H., O'Boyle, D.R. 2nd, Nower, P., Valera, L., et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54 (2011), 1924–1935.
21. Liu, R., Curry, S., McMonagle, P., Yeh, W.W., Ludmerer, S.W., Jumes, P.A., et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 59 (2015), 6922–6929.
22. Krishnan, P., Beyer, J., Mistry, N., Koev, G., Reisch, T., DeGoey, D., et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59 (2015), 979–987.